SoFi stock falls after announcing $1.5B public offering of common stock
Benitec Biopharma Inc. (NASDAQ:BNTC) announced the results of its 2025 Annual Meeting of Stockholders, held virtually on Monday. According to a press release statement and SEC filing, 22,327,761 shares, representing 85.06% of the company’s outstanding common stock, were present or represented by proxy.
Shareholders voted on three proposals. The first proposal was the election of two directors. Dr. Jerel Banks received 22,150,169 votes in favor and 101,379 votes withheld, while Megan Boston received 21,693,741 votes in favor and 557,807 votes withheld. There were 76,213 broker non-votes for each nominee. Both directors were elected.
The second proposal was the ratification of the appointment of the company’s independent registered public accounting firm. This proposal received 22,252,834 votes in favor, 4,787 votes against, and 70,140 abstentions.
The third proposal was an advisory vote on executive compensation. It received 17,239,339 votes for, 4,939,686 votes against, and 72,523 abstentions, with 76,213 broker non-votes.
Each proposal received the required number of votes for approval.
Benitec Biopharma Inc. is listed on The Nasdaq Stock Market LLC under the symbol BNTC. All information is based on a press release statement and the company’s SEC filing.
In other recent news, Benitec Biopharma announced the pricing of a $100 million stock offering, selling shares at $13.50 each. This offering includes 5.93 million shares in an underwritten public offering and 1.48 million shares in a registered direct offering to Suvretta Capital. The company has also provided underwriters a 30-day option to purchase an additional 889,500 shares under the same terms. H.C. Wainwright adjusted its price target for Benitec Biopharma to $32.00, down from $35.00, while maintaining a Buy rating. This adjustment followed Benitec’s recent equity financing transaction. Meanwhile, Citizens reiterated its Market Outperform rating with a $22.00 price target, citing encouraging efficacy data for Benitec’s BB-301 treatment. The investment firm expressed optimism about improvements in the complete Cohort 1 data set and plans to monitor future updates. These developments reflect the company’s ongoing financial and clinical activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.